JW THERAP-B(02126): Tian Feng will be appointed as the Chief Executive Officer.

JW THERAP-B (02126) announces that Mr. Tian Feng (Mr. Tian) will be appointed as the company's Chief Executive Officer and Executive Director, effective from December 29, 2025. Dr. Liu Cheng (Dr. Liu) is appointed as the Chairman of the Board of Directors, effective from December 12, 2025. The Board of Directors further announces that Mr. Liu Min (Mr. Liu), the current Executive Director, Chairman, and Chief Executive Officer of the company, has resigned from his positions as Executive Director, Chairman, and Chief Executive Officer of the company, as well as from the Nomination Committee and Business Development and Strategy Committee, as of December 12, 2025, for personal career development reasons. Following the appointment of Mr. Tian and the resignation of Mr. Liu, the Board of Directors hereby announces that Mr. Tian will be appointed as a member of the Nomination Committee and Business Development and Strategy Committee, effective from December 29, 2025. The Board of Directors also announces the appointment of Dr. Liu to replace Mr. Liu as the authorized representative of the company as per Rule 3.05 of the Listing Rules, effective from December 12, 2025. Following these changes, the authorized representatives of the company are Dr. Liu and the company secretary, Ms. Wu Jiawen (Ms. Wu). The Board of Directors further announces that Mr. Tian will be appointed as an authorized representative to replace Dr. Liu, effective from December 29, 2025. As of December 29, 2025, the authorized representatives of the company are Mr. Tian and Ms. Wu. In addition, on September 16, 2025, the Board of Directors approved a proposal to grant a total of 4.45 million share options to Mr. Liu under an incentive plan after the initial public offering, subject to approval by the shareholders (granted in September 2025). However, considering the delay in sending the relevant communication and notice of the shareholders' special meeting regarding the grant in September 2025, and Mr. Liu's resignation taking effect before the shareholders' special meeting, the Board of Directors further announces that the grant in September 2025 will be canceled effective from December 12, 2025. The cancellation of the grant in September 2025 has been agreed upon by Mr. Liu.